Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

2185

HKSE:2185

Shanghai Bio-heart Biological Technology Co., Ltd.

Last Close

1.40

30/08 05:48

Market Cap

812.22M

Beta: −0.43

Volume Today

6.90K

Avg: 26.51K

PE Ratio

−1.80

PFCF: −9.37

locale

market

industry

website

ipo date

peer of

Metrics